Expanding Orthopedics was granted two additional U.S. Patents covering expandable interbody cage technology.
In 1Q17, the company announced achievement of its largest revenue quarter to date. This followed 2H16 revenue growth up 100% vs. the previous year. Growth is attributed to rapid surgeon adoption of the FLXfit™ expandable cage and to overall market uptake of expandable cages, in general.
FLXfit technology received FDA 510(k) clearance and CE Mark approval in 2014. In 2Q17, the company launched FLXfit15, an interbody cage that expands up to 4mm and enables controlled lordosis correction of up to 15⁰. The higher range expansion is intended to support restoration of the lordosis angle up to 15⁰, while availability in a 32mm length can address smaller anatomies.
Expanding Orthopedics was granted two additional U.S. Patents covering expandable interbody cage technology.
In 1Q17, the company announced achievement of its largest revenue quarter to date. This followed 2H16 revenue growth up 100% vs. the previous year. Growth is attributed to rapid surgeon adoption of the FLXfit™ expandable cage...
Expanding Orthopedics was granted two additional U.S. Patents covering expandable interbody cage technology.
In 1Q17, the company announced achievement of its largest revenue quarter to date. This followed 2H16 revenue growth up 100% vs. the previous year. Growth is attributed to rapid surgeon adoption of the FLXfit™ expandable cage and to overall market uptake of expandable cages, in general.
FLXfit technology received FDA 510(k) clearance and CE Mark approval in 2014. In 2Q17, the company launched FLXfit15, an interbody cage that expands up to 4mm and enables controlled lordosis correction of up to 15⁰. The higher range expansion is intended to support restoration of the lordosis angle up to 15⁰, while availability in a 32mm length can address smaller anatomies.
Copy to clipboard 
